Common Contracts
17 similar Underwriting Agreement contracts by Bluebird Bio, Inc., Evolus, Inc., Insys Therapeutics, Inc., others
bluebird bio, Inc. 95,833,332 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • December 20th, 2023 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
bluebird bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 83,333,333 shares (the “Firm Securities”) of common stock, par value $0.01 per share (“Stock”) and, at the election of the Underwriters, up to 12,499,999 additional shares of Stock (the “Optional Securities”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
bluebird bio, Inc. 20,000,000 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • January 19th, 2023 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
bluebird bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 20,000,000 shares (the “Firm Securities”) of common stock, par value $0.01 per share (“Stock”) and, at the election of the Underwriters, up to 3,000,000 additional shares of Stock (the “Optional Securities”) of the Company (the Firm Securities and the Optional Securities that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Securities”).
FIRST WATCH RESTAURANT GROUP, INC. (a Delaware corporation) [4,500,000] Shares of Common Stock FORM OF UNDERWRITING AGREEMENTUnderwriting Agreement • September 12th, 2022 • First Watch Restaurant Group, Inc. • Retail-eating places • New York
KKR REAL ESTATE FINANCE TRUST INC. 5,000,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: October 27, 2021Underwriting Agreement • November 1st, 2021 • KKR Real Estate Finance Trust Inc. • Real estate investment trusts • New York
EVOLUS, INC. (a Delaware corporation) 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2021 • Evolus, Inc. • Pharmaceutical preparations • New York
Evolus, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Leerink LLC (“SVB Leerink”), Stifel, Nicolaus & Company, Incorporated (“Stifel”), Cantor Fitzgerald & Co. (“CF&Co.”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Leerink, Stifel and CF&Co. are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.00001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 1,350,000 additional shares of Common Stock. The af
Ayala Pharmaceuticals, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 6th, 2020 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This letter agreement is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”), among Ayala Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of you as representatives (the “Representatives”) of a group of Underwriters named therein, relating to an underwritten public offering of Common Stock, $0.01 par value (the “Common Stock”), of the Company (the “Offering”).
UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2019 • Evolus, Inc. • Pharmaceutical preparations • New York
Evolus, Inc., a Delaware corporation (the “Company”), confirms its agreement with SVB Leerink LLC (“SVB Leerink”), Stifel, Nicolaus & Company, Incorporated (“Stifel”), Cantor Fitzgerald & Co. (“CF&Co.”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for which SVB Leerink, Stifel and CF&Co. are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.00001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 782,550 additional shares of Common Stock. The afor
SeaSpine Holdings Corporation 3,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 11th, 2018 • SeaSpine Holdings Corp • Surgical & medical instruments & apparatus • New York
CHESAPEAKE UTILITIES CORPORATION 835,207 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 28th, 2016 • Chesapeake Utilities Corp • Natural gas transmisison & distribution • New York
RIVER VALLEY BANCORP (an Indiana corporation) [·] Shares of Common Stock (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • June 13th, 2014 • River Valley Bancorp • Savings institution, federally chartered • New York
RIVER VALLEY BANCORP (an Indiana corporation) [·] Shares of Common Stock (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2014 • River Valley Bancorp • Savings institution, federally chartered • New York
IMMUNOMEDICS, INC. 9,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 2nd, 2014 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
ZOGENIX, INC. 26,666,667 Shares Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 6th, 2013 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”), Leerink Swann LLC (“Leerink”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Stifel and Leerink are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 26,666,667 shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of the 4,000,000 addi
BIOCRYST PHARMACEUTICALS, INC. 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 5th, 2013 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 16th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
ZOGENIX, INC. 32,500,000 Units Consisting of One Share of Common Stock and A Warrant to Purchase 0.45 of a Share of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2012 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Stifel and Wells Fargo are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 32,500,000 units (the “Initial Securities”), each unit consisting of (i) one share (each, a “Share”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) a warrant to purchase 0.45 of a share of Common Stock (each, a “Warrant”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Co
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2011 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
